Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Authors
Keywords
-
Journal
Diabetes Technology & Therapeutics
Volume 13, Issue 12, Pages 1219-1227
Publisher
Mary Ann Liebert Inc
Online
2011-08-20
DOI
10.1089/dia.2011.0012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
- (2013) Muhammad Abdul-Ghani et al. Endocrine Practice
- SGLT2 inhibitors: molecular design and potential differences in effect
- (2011) Masayuki Isaji KIDNEY INTERNATIONAL
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Sodium-Glucose Co-Transport Inhibitors
- (2010) Joshua J. Neumiller et al. DRUGS
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
- (2010) Faramarz Ismail-Beigi et al. LANCET
- Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects
- (2009) W. T. CEFALU et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
- (2009) L. BLONDE CLEVELAND CLINIC JOURNAL OF MEDICINE
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- (2009) J. E. Gerich DIABETIC MEDICINE
- Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
- (2009) Sunil Nair et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes
- (2008) S. A. Jabbour et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now